Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole‐body fat‐referenced MRI: Protocol development, multicenter feasibility, and repeatability. Issue 2 (11th June 2022)

• Record Type: Journal Article
• Authors: Widholm, Per; Ahlgren, André; Karlsson, Markus; Romu, Thobias; Tawil, Rabi; Wagner, Kathryn R.; Statland, Jeffrey M.; Wang, Leo H.; Shieh, Perry B.; van Engelen, Baziel G. M.; Cadavid, Diego; Ronco, Lucienne; Odueyungbo, Adefowope O.; Jiang, John G.; Mellion, Michelle L.; Dahlqvist Leinhard, Olof
• Is Part Of: Muscle & nerve. Volume 66:Issue 2(2022)
• Page Start: 183
• Page End: 192
• Publication Date: 2022-06-11
• Subjects: facioscapulohumeral muscular dystrophy -- magnetic resonance imaging -- muscle disease -- quantitative muscle analysis -- volumetric magnetic resonance imaging; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.27638
• Languages: English
• ISSNs: 0148-639X

Abstract

Abstract: Introduction/Aims: Functional performance tests are the gold standard to assess disease progression and treatment effects in neuromuscular disorders. These tests can be confounded by motivation, pain, fatigue, and learning effects, increasing variability and decreasing sensitivity to disease progression, limiting efficacy assessment in clinical trials with small sample sizes. We aimed to develop and validate a quantitative and objective method to measure skeletal muscle volume and fat content based on whole‐body fat‐referenced magnetic resonance imaging (MRI) for use in multisite clinical trials. Methods: Subjects aged 18 to 65 years, genetically confirmed facioscapulohumeral muscular dystrophy 1 (FSHD1), clinical severity 2 to 4 (Ricci's scale, range 0–5), were enrolled at six sites and imaged twice 4–12 weeks apart with T1‐weighted two‐point Dixon MRI covering the torso and upper and lower extremities. Thirty‐six muscles were volumetrically segmented using semi‐automatic multi‐atlas‐based segmentation. Muscle fat fraction (MFF), muscle fat infiltration (MFI), and lean muscle volume (LMV) were quantified for each muscle using fat‐referenced quantification. Results: Seventeen patients (mean age ± SD, 49.4 years ±13.02; 12 men) were enrolled. Within‐patient SD ranged from 1.00% to 3.51% for MFF and 0.40% to 1.48% for MFI in individual muscles. For LMV, coefficients of variation ranged from 2.7% to 11.7%. For the composite score average of all muscles, observed SDs were 0.70% and 0.32% for MFF and MFI, respectively; composite LMV coefficient of variation was 2.0%. Discussion: We developed and validated a method for measuring skeletal muscle volume and fat content for use in multisite clinical trials of neuromuscular disorders.